Bristol-Myers to buy Celgene for $74 bln

Cancer drugmaker Bristol-Myers Squibb Co said on Thursday it would buy Celgene Corp for about $74 billion in a cash-and-stock deal.

Celgene shareholders will receive one Bristol-Myers Squibb share and $50 in cash for each share held, or $102.43 per share, a premium of 53.7 percent to Celgene's Wednesday close.

(Reporting by Ankur Banerjee in Bengaluru; Editing by Arun Koyyur)